UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended ~~September~~December 3031, ~~2005.~~2006

¨o Transition Report to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the Transition Period from ~~_______________~~ _________ to ~~_______________~~_________.

000-28371

(Commission File Numbers)

ENDOVASC, INC.

(Exact name of registrant as specified in its charter)

NEVADA	76-0512500
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification No.)

550 Club Drive, Suite ~~440~~345

Montgomery, Texas 77316

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (936) 582-5920

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. ~~(as~~See ~~defined~~definition inof “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange ~~Act). Yes ¨~~ ~~No x~~Act.

~~Indicate by~~Large ~~check~~Accelerated ~~mark~~Filer ~~whether~~o ~~the~~Accelerated ~~registrant~~Filer iso ~~a shell company (as defined in Rule 12b~~Non-2Accelerated ofFiler ~~the Exchange Act). Yes ¨ No~~ x

~~APPLICABLE~~Indicate ~~ONLY~~by TOcheck ~~ISSUERS~~mark ~~INVOLVED~~whether INthe ~~BANKRUPTCY~~registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yeso No x

~~PROCEEDINGS~~There ~~DURING~~were ~~THE~~160,981,519 ~~PRECEDING~~shares ~~FIVE~~of ~~YEARS:~~Common Stock, $.001 par value per share, and 14,158,593 shares of Series NDC Common Stock, $.001 par value per share outstanding as of February 20, 2007.

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ¨ No ¨1

As of November 10, 2005, 119,118,519 and 14,158,593 shares of Common Stock-Endovasc Series and Common Stock-NDC Series, respectively, par value $.001 per share, of Endovasc, Inc. were outstanding.

PART I

FINANCIAL INFORMATION

Item 1.	Financial Statements
	Balance Sheets as of September 30, 2005 and June 30, 2005	3
	Statements of Net Assets as of December 31, 2006 and June 30, 2006	3
	Statements of Operations for the three months ended September 30, 2005 and September 30, 2004	4
	Statements of Operations for the three months ended December 31, 2006 and 2005 and for the six months ended December 31, 2006 and 2005	4
	Statement of Stockholders’ Equity for the three months ended September 30, 2005	5
	Statements of Cash Flows for the six months ended December 31, 2006 and 2005	5
	Statements of Cash Flows for the three months ended September 30, 2005 and September 30, 2004	6
	Statements of Changes in Net Assets for the six months ended December 31, 2006 and 2005	6
	Schedule of Investments	7
	Financial Highlights	7
	Notes to Financial Statements	8
	Schedule of Investments	8
	Notes to Unaudited Condensed Financial Statements	9

Table of Contents

~~PART I FINANCIAL INFORMATION~~Endovasc, Inc.

~~Item~~Statements of 1Net ~~Financial Statements~~Assets

Endovasc, Inc

Balance Sheets

__________

(In thousands, except share data)

	Sep 30, 2005			June 30, 2005
	December 31, 2006			June 30, 2006
Assets	~~(unaudited)~~			(audited)
Investments:
Investment in controlled companies, at fair value	$	~~710~~2,000		$	1,605
(cost of $742)
(cost of $1,218 at December 31, 2006 and $1,168 at June 30, 2006)
Cash and cash equivalents		7630			~~116~~20
Other assets		10			14
Subscriptions receivable		-			25
Property and equipment, net		32			37
Prepaid expenses		16			35
Total	$	828			772
Property and equipment, net		23			29
Liabilities and stockholders' equity
Total assets		2,069			1,714
Current maturities of long-term debt	$	34			42
Liabilities
Capital leases		18			28
Notes payable		18			46
Notes payable		105			115
Notes payable- stockholders		80			105
Accounts payable and accrued liabilities		238			230
Capital leases		8			15
Accounts payable and accrued liabilities		284			303
Convertible debentures		1			1
Total liabilities		~~396~~391			~~416~~470
Net assets		1,678			1,244
Commitments and contingencies		-			-
Stockholdes' equity:
Composition of net assets:
Common stock, $.001 par value, 200,000,000 shares authorized
Common stock, $.001 par value, 500,000,000 shares authorized 160,981,519 and 146,694,319 shares outstanding at December 31, 2006 and June 30, 2006 respectively		160			147
Common stock-Endovasc Series, 111,537,569 shares outstanding at September 30, 2005		111			104
Series NDC common stock, 14,158,593 shares issued and outstanding		14			14
Common stock - NDC Series, 14,158,593 shares issued and outstanding at September 30, 2005		14			14
Preferred stock, $.001 par value, 20,000,000 shares authorized, 208 shares of Series A 8% cumulative convertible preferred stock issued and outstanding		-			-
Preferred stock, $.001par value, 20,000,000 shares authorized, 208 shares of Series A 8% cumulative convertible preferred stock issued and outstanding at September 30, 2005 stated value $100 per share		-			-
Additional paid-in capital		28,012			27,700
Additional paid-in capital		26,859			26,630
Accumulated deficit:
Accumulated deficit		(26,520	)		(26,329	)
Accumulated net operating loss		(27,290	)		(27,054	)
Unrealized depreciation on investments		(32	)		(63	)
Unrealized appreciation on investments		782			437
Total stockholders' equity		432			356
Net assets	$	1,678		$	1,244
Total liabilities and stockholders' equity	$	828			772
Net assets value per share
Common stock	$	0.0095		$	0.0069
Series NDC common stock	$	0.0008		$	0.0008

The accompanying notes are an integral part of these financial statements

Table of Contents

Endovasc, Inc.

Statements of Operations

(Unaudited)

__________

(In thousands, except share data)

	Three months ended September 30, 2005			Three months ended September 30, 2004
	THREE MONTHS ENDED						SIX MONTHS ENDED
Income:
	December 31, 2006			December 31, 2005			December 31, 2006			December 31, 2005
Revenue	$	35		$	-
Operating Income
Other income		3			-
Management fees	$	84		$	54		$	138		$	89
Total income		38			-
Other Income		-			73			26			73
Costs and expenses:
Total income		84			127			164			162
Operating, general and administrative expenses		229			501
Operating expenses
Research and development costs		-			86
General and administrative		149			276			310			491
Interest expense		-			7
Professional fees		66			50			88			62
Total costs and expenses		229			594
Interest expense		1			-			2			-
Operating loss before investment loss		(191	)		(594	)
Total operating expenses		216			326			400			553
Unrealized appreciation of portfolio investments		31			-
Operating loss		(132	)		(199	)		(236	)		(391	)
Loss attributed to minority interest		-			-
Net realized and unrealized gains
Net loss	$	(160	)	$	(594	)
Unrealized appreciation (depreciation) of portfolio investments		(5	)		(39	)		345			(7	)
Net profit (loss) available to common stockholders	$	(160	)	$	(594	)
Net increase (decrease) in net assets from operations	$	(137	)	$	(238	)	$	109		$	(398	)
Weighted average shares outstanding		103,127,329			71,697,112
Net increase (decrease) in net assets from operations per share:
Basic and diluted net loss per common share	$	0.00		$	0.00
Basic and diluted, Common stock	$	(0,000	)	$	(0,000	)	$	0,000		$	(0,000	)
Basic and diluted, Series NDC	$	(0,000	)	$	(0,000	)	$	0,000		$	(0,000	)
Weighted average common shares outstanding:
Basic and diluted, common stock		159,620,843			103,127,329			155,659,204			108,295,668
Basic and diluted, Series NDC common stock		14,158,593			14,158,593			14,158,593			14,158,593

The accompanying notes are an integral part of these financial statements

Table of Contents

~~ENDOVASC~~Endovasc, ~~INC~~Inc

~~STATEMENT~~Statements OFof ~~STOCKHOLDERS’~~Cash ~~EQUITY~~Flows

(~~unaudited~~In thousands)

For the period ened September 30, 2005

	Six Months Ended December 31, 2006			Six Months Ended December 31, 2005
Cash flows from operating activities:
Net Income (loss)	$	109		$	(398	)
Adjustments to reconcile net Income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization		6			7
Unrealized appreciation/(depreciation) on investments		(345	)		7
Grant of stock options		-			93
Other assets/prepaid expenses		44			(62	)
Accounts payable and accrued liabilities		(19	)		21
Investment in portfolios		(50	)		(112	)
Net cash used in operating activities		(255	)		(444	)

Cash flows from financing activities:
Proceeds from sale of common stock		325			377
Repayment of long-term debt and notes payable		(28	)		(12	)
Payments of obligations under capital leases		(7	)		(18	)
Repayments of notes to stockholders		(25	)		(10	)
Net cash provided by financing activities		265			337

Net increase/(increase) in cash and cash equivalents		10			(107	)

Cash and cash equivalents, beginning of period		20			116

Cash and cash equivalents, end of period	$	30		$	9

Supplemental disclosure of cash flow information:
Cash paid for interest	$	2		$	1

(In thousands, except share data)

	Common Stock Endovasc Series				Common Stock NDC Series				Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock
	Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Additional Paid-In Capital		Treasury Stock		Accumulated Deficit			Unrealized (Depreciation) Appreciation			Total
Balance at June 30 2005	$	104		104,432,179	$	14		14,158,593			$	208					$			-		26,630			$	(26,329	)	$	(63	)	$	356
Issuance of Common Stock For Cash		7		7,105,390		-		-		-		-		-		-		-		-		229										236
Net loss		-		-		-		-		-		-		-		-		-		-		-		-		(191	)		31			(160	)
Balance at September 30, 2005	$	111		111,537,569	$	14		14,158,593			$	208			$	-			$	-		26,859		-	$	(26,520	)	$	(32	)	$	432

The accompanying notes are an integral part of these financial statements

Table of Contents

Endovasc, Inc.

Statements of ~~Cash~~Changes ~~Flows~~in Net Assets

(~~unaudited~~in thousands)

(In Thousands)

	Six Months Ended Dec 31 2006			Six Months Ended Dec 31 2005
Changes in net assets from operations:
Operating Loss	$	(236	)	$	(391	)
Changes in unrealized appreciation/(depreciation) on investment, net		345			(7	)
Net increase/(decrease) in net assets from operations		109			(398	)

Capital stock transaction - Common stock:
Issuance of common stock for cash		325			377
Grant of employee stock options		-			93
Net increase in net assets from common stock transactions		325			470
Net increase in net assets		434			72
Net assets, beginning of period		1,244			356
Net assets, end of period	$	1,678		$	428

	Three Month ended September 30, 2005			Three months ended September 30, 2004
Cash flows from operating activities:
Net Income (loss)	$	(160	)		(594	)
Adjustments to reconcile net inome(loss) to net cash (used in) provided by oeprating activities:
Common stock, preferred stock and warrants issued as compensation for services, financing and settlement		-			313
Depreciation and amortization		5			16
Unrealized appreciation on investments		(31	)		-
Changes in operating assets and liabilities:
Other assets		4			62
Accounts payable and accrued liabilities		8			74
Deferred liabilities		-			(4	)
Net cash used in operating activities		(174	)		(133	)
Cash flows from investing activities:
Investment in subsidiaries		(74	)		-
Net cash used in investing activities		(74	)		-
Cash flows from financing activities:
Proceeds from sale of common stock		236			-
Issuance of long-term debt and notes payable		-			5
Repayment of long-term debt and notes payable		(8	)		(5	)
Payments of obligations under capital leases		(10	)		(5	)
Proceeds from advances from stockholders		-			77
Repayments of notes to stockholders		(10	)		(55	)
Net cash provided by financing activities		208			17
Net decrease in cash and cash equivalents		(40	)		(116	)
Cash and cash equivalents, beginning of period		116			116
Cash and cash equivalents, end of period	$	76			-

The accompanying notes are an integral part of these financial statements

Table of Contents

~~ENDOVASC~~Endovasc, ~~INC~~Inc.

~~Schedule~~Financial ~~of Investments~~Highlights

Portfolio Companies	Industry		Title of Security Held by Company		Percentage of Class Held			Sep 30, 2005 Fair Value		June 30, 2005 Fair Value
								(unaudited)		(audited)
Investments in equity securities:
Liprostin, Inc		Biopharmaceutical		Common Stock		100	%	$	250,000	$	400,000
Angiogenix, Ltd Inc		Biopharmaceutical		Common Stock		100	%		5,000		25,000
Nutraceutical Development Corp		Biopharmaceutical		Common Stock		100	%		450,000		175,000
Investments in joint ventures:
Endovasc-TissueGen Research Sponsors, L.L.C		Biopharmaceutical		Equity/Debt		49.90	%		2,500		2,500
Endovasc-TissueGen-Blumberg Research Sponsors, L.L.C		Biopharmaceutical		Equity/Debt		39.90	%	$	2,500	$	2,500

(In thousands, except share data)

	Common stock						Series NDC Common stock

	Six Months Ended Dec 31, 2006			Six Months Ended Dec 31, 2005			Six Months Ended Dec 31, 2006			Six Months Ended Dec 31, 2005
PER SHARE INFORMATION
Net asset value, beginning of period *	$	0.0069		$	0.0026		$	0.0008		$	0.0004
Net increase (decrease) from operating		(0.0013	)		(0.0026	)		(0.0001	)		(0.0003	)
Net change unrealized appreciation of investments, net		0.0019			0.0001			0.0001			-
Net increase from stock transactions		0.0020			0.0035			-			-

Net asset value, end of period	$	0.0095		$	0.0036		$	0.0008		$	0.0001


PER SHARE MARKET VALUE:
Beginning of period	$	0.0320		$	0.0430		$	0.0500		$	0.0770
End of period	$	0.0300		$	0.0212		$	0.0500		$	0.0550

Investment return, based on market price at end of period (1)		13	%		64	%		0.0	%		0.0	%
(1) Periods of less than one year are not annualized.

RATIOS/SUPPLEMENTAL DATA
Net assets, end of period	$	1,542		$	381		$	136		$	47
Average net assets	$	1,344		$	349		$	117		$	43
Annualized ratio of expenses to average net assets		487	%		255	%		0	%		0	%
Annualized ratio of net increase (decrease) in net assets from operations to average net assets from		-351	%		-2241	%		73	%		352	%
Shares outstanding at end of period		160,981,519			118,818,519			14,158,593			14,158,593
Weighted average shares outstanding during period		155,659,204			108,295,668			14,158,593			14,158,593

* Restated - See note 2

The accompanying notes are an integral part of these financial statements

Table of Contents

~~ENDOVASC~~Endovasc, ~~INC~~Inc.

~~NOTES~~Schedule TOof ~~UNAUDITED CONDENSED FINANCIAL STATEMENTS~~Investments

~~__________~~(In thousands, except share data)

(IN THOUSANDS, EXCEPT SHARE DATA)

								Dec 31, 2006				June 30, 2006
Portfolio Companies	Industry	Title of Security Held by Company	Number of Shares Held		% of Class Held			Cost		Fair Value		Cost		Fair Value

Investments in equity securities

Liprostin, Inc	Biopharmaceutical	Common Stock		10,000,000		100	%	$	823	$	800	$	773	$	600

Angiogenix, LTD Inc	Biopharmaceutical	Common Stock		10,000,000		100	%		34		-		34		-

Nutraceutical Development Corporation	Biopharmaceutical	Common Stock		75,000,000		100	%		89		1,200		89		1,000

Investments in joint ventures

Endovasc-TissueGen Research Sponsors, LLC	Biopharmaceutical	Equity/Debt		n/a		49.90	%		55		-		55		3

Endovasc-TissueGen-Blumberg Research Sponsors, LLC	Biopharmaceutical	Equity/Debt		n/a		39.90	%		217		-		217		2

								$	1,218	$	2,000	$	1,168	$	1,605

The accompanying notes are an integral part of these financial statements

Table of Contents

Notes to the Unaudited Condensed Financial Statements

(In thousands except share data)

1.	Interim Financial Statements

The accompanying interim condensed financial statements and notes to the financial statements for the interim ~~periods~~period as of ~~September~~December 3031, ~~2005~~2006 and for the three and six months ended ~~September~~December 3031, ~~2005 and 2004~~2006, are unaudited. The accompanying interim ~~interim~~ unaudited financial statements have been prepared by the Company in accordance ~~accordance~~ with accounting principles generally accepted in the United States of America for interim financial statements and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three ~~month~~months ~~period~~and six months ended ~~September~~December 3031, ~~2005~~2006, are not necessarily indicative of ~~the~~ the results that may be expected for the year ending June 30, ~~2006~~2007. The ~~condensed~~ condensed financial statements should be read in conjunction with the financial ~~statements~~ statements and notes thereto included in the Form 10-~~KSB~~K of the Company as of ~~and for~~ ~~the~~and for the year ended June 30, ~~2005~~2006.

In accordance with Article 6 of Regulation S-X under the Securities Act of 1933 and Securities Exchange Act of 1934, the Company does not consolidate portfolio company investments in which the Company has a controlling interest.

2.	Organization and Summary of Significant Accounting Policies

Endovasc, Inc. (the "Company") is incorporated under the laws of the State of Nevada. On October 6, 2004 the Company filed its election with the SEC (Form N-54A) to adopt business development company ("BDC") status under the Investment Company Act of 1940 ("1940 Act"). A BDC is a specialized type of investment company under the 1940 Act. A BDC may primarily be engaged in the business of furnishing capital and managerial expertise to companies that do not have ready access to capital through conventional financial channels; such companies are termed "eligible portfolio companies". The Company, as a BDC, may invest in other securities; however, such investments may not exceed 30% of the Company's total asset value at the time of such investment. The accompanying financial statements reflect the accounts of Endovasc, Inc., and the related results of operations. In accordance with Article 6 of Regulation S-X under the Securities Act of 1933 and Securities Exchange Act of 1934, the Company does not consolidate portfolio company investments in which the Company has a controlling interest. Accounting principles used in the preparation of the financial statements beginning October 6, 2004 are different than those of prior periods and, therefore, the financial position and results of operations of these periods are not directly comparable. The primary differences in accounting principles relate to the carrying value of investments.

Accounting principles used in the preparation of the financial statements beginning October 6, 2004 are different than those of prior periods and, therefore, the financial position and results of operations of these periods are not directly comparable. The primary differences in accounting principles relate to the carrying value of investments. The Company has two classes of common shares (common stock and series NDC common stock). Both classes have identical rights, preferences, privileges and restrictions, except that the series NDC common stock was entitled to certain preferences in dividends, distributions and other rights relating to the performance of the nutraceutical application of the Company’s angiogenic patents, licenses, products and services. As of December 31, 2006, the Company did not have any angiogenic patents, licenses, products and services and the series NDC common stock was not entitled to any preferences in relation to the shares of common stock.

The Company currently has investments in five portfolio companies as follows:

Liprostin, Inc.

The Company has aninvested ~~investment~~ in ~~the wholly-owned, unconsolidated subsidiary,~~ Liprostin, Inc., ~~which~~a iswholly-owned ~~engaged~~portfolio ~~in the development of liposome drug delivery~~company ~~systems.~~engaged ~~Liposomes,~~in ~~which~~obtaining ~~are~~FDA ~~microscopic~~approval ~~cell-like spheres composed~~ of a ~~thin,~~liposomal ~~durable~~encapsulated ~~lipid~~form ~~membrane surrounding a hollow compartment,~~of ~~can be~~Prostaglandin ~~used~~1-E tofor ~~entrap and protect drugs from degradation in~~ the ~~blood~~treatment ~~stream and can be engineered to regulate the transport~~ of ~~molecules~~intermittent ~~across their outer membrane~~claudication.

~~Angiogenix Limited, Inc.~~9

The Company also has an investment in the wholly-owned, unconsolidated subsidiary, Angiogenix Limited, Inc (Angiogenix). Angiogenix has an exclusive licensing agreement (the "Stanford License Agreement") with the Board of Trustees of the Leland Stanford University relating to US Patent Application 60/146,233 (issued as US Patent No. 6,417,205 B1 on July 9, 2002) relating to the administration of Nicotine or Nicotine Receptor Agonist (NRA) to induce the growth of new blood vessels ("angiogenesis"). During the quarter ended June 30, 2005, the Company canceled its license agreement with Leland J. Stanford University.

Table of Contents

Notes to the Unaudited Condensed Financial Statements

~~ENDOVASC,~~(In ~~INC.~~thousands except share data)

~~NOTES~~Angiogenix TO Limited, ~~UNAUDITED CONDENSED FINANCIAL STATEMENTS~~Inc.

~~__________~~The Company has invested in Angiogenix Limited, Inc., a wholly-owned portfolio company that previously held an exclusive licensing agreement (the "Stanford License Agreement") relating to US Patent No. 6,417,205 B1 relating to the administration of Nicotine or Nicotine Receptor Agonist (NRA) to induce the growth of new blood vessels ("angiogenesis"). During the year ended June 30, 2005, the Company cancelled the Stanford License Agreement and Angiogenix Limited, Inc. ceased operations.

(IN THOUSANDS, EXCEPT SHARE DATA)

Nutraceutical Development Corporation

The Company has aninvested ~~investment~~ in ~~the wholly-owned, unconsolidated subsidiary,~~ Nutraceutical Development Corporation, ~~("NDC").~~a ~~NDC was formed to develop certain~~wholly-owned ~~technologies~~portfolio ~~now~~company ~~owned~~engaged byin the ~~Company's~~development ~~other~~of ~~subsidiaries~~certain technologies for use in ~~dietary~~ dietary products designed to enhance health and provide beneficial biological effects. Nutraceutical Development Corporation is currently receiving royalties ~~("nutraceuticals")~~for the license of its proprietary muscle mass technology.

Endovasc-TissueGen Research Sponsors, L.C.C.

The Company has ainvested ~~49.9% investment~~ in ~~a joint venture named~~ Endovasc-TissueGen Research Sponsors, L.L.C., ~~(the~~a ~~"Partnership")~~49.9% owned ~~The~~limited ~~purpose~~liability ofcompany engaged in the ~~Partnership is to~~development ~~develop~~of a bioresorbable drug-eluting cardiovascular stent for the advanced treatment of coronary artery disease.

Endovasc-TissueGen-Blumberg Research Sponsors, L.C.C

The Company has ainvested ~~39.9% investment~~ in ~~a joint venture named~~ Endovasc-TissueGen -Blumberg Research Sponsors, L.L.C., a 39.9% owned ~~(the~~limited ~~"Joint~~liability ~~Venture").~~company ~~The~~engaged ~~purpose~~in of the development of ~~Joint~~biodegradable ~~Venture~~stents isfor toureteral ~~develop~~and ~~biodegradable~~prostate applications.

stents for ureteral and prostate applications.

Significant Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. While it is believed that such estimates are reasonable, actual results could differ from those estimates.

AsInvestment a business development company, the Company's investments are in private companies with no publicly available market price. Business development companies are required to carry investments at fair value. Generally, the fair value of a private security will initially be based primarily on its original cost to the Company. Management and the Company's board of directors must evaluate the actual and expected future operations of the portfolio companies, monitor market conditions and evaluate any new financings or other significant events that the portfolio companies may sustain in order to estimate a fair value for the investments in these companies at least quarterly. If the Company's estimates of the future differ from actual events in the future, for any reason, the Company may fail to record an unrecognized gain or loss or may record it later or earlier than it would with a perfect forecast of the future. Because these investments are restricted and illiquid, even if the Company correctly estimates a fair value for an investment today, that investment could lose some or all of its value in the near future without the Company realizing any benefit from its investments or recognizing any cash proceeds from the sale of these investments. If, in the future, the Company determines that a loss has occurred in any of its investments, that loss will be reflected as a reduction in the value of its investments on the Company's consolidated balance sheet, and the reduced values will negatively impact earnings and be reflected as a loss on the statements of operations.Valuation

9Investments are carried at fair value as determined in good faith by or under the direction of the Board of Directors of the Company based on information, including an independent valuation, and using valuation methodologies considered appropriate and reliable by the Board. Generally, the fair value of a private security will initially be based primarily on its original cost to the Company. Cost will be the primary factor used to determine fair value on an ongoing basis until significant developments or other factors affecting the investment (such as results of the portfolio company's operations, changes in general market conditions, subsequent financings, independent valuations or the availability of market quotations) provide a basis for value other than cost. For investments in which the Company earns an interest for services rendered, the Board estimates the fair value of the services as the initial basis for estimating fair value of the securities received. The Board believes that the methods used to value the investments reflected in the accompanying financial statements have been valued appropriately and that the values reflected herein have been calculated in accordance with generally accepted valuation methods which result in valuations in the Company's financial statements being recorded in accordance with generally accepted accounting principles in the United States of America. However, losses may occur, which may be material to the financial condition of the Company and proceeds, if any, from the disposition of securities could differ significantly from the values reflected herein. In particular, early stage and seed round investments in private companies, which is the focus of the Company, are typically in illiquid restricted securities with no current market and therefore no market prices or comparables are available upon which to base estimates. These factors, among others, make determination of fair value more difficult and subject to significant judgment errors by the Company's board of directors.

Table of Contents

ENDOVASC, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

__________

(IN THOUSANDS, EXCEPT SHARE DATA)

Investments

The Company's investments potentially subject the Company to various levels of risk associated with economic changes, interest rate fluctuations, political events, war and terrorism, and operating conditions beyond the control of the Company. Consequently, management's judgment as to the level of losses that currently exist or may develop in the future, if any, involves the consideration of current and anticipated conditions and their potential effects on the Company's investments. Due to the level of risk associated with investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term could materially impact the value of the amounts reflected in the accompanying financial statements. Investments are carried at fair value as determined in good faith by or under the direction of the Board of Directors of the Company based on information, including an independent valuation, and using valuation methodologies considered appropriate and reliable by the Board. Generally, the fair value of a private security will initially be based primarily on its original cost to the Company. Cost will be the primary factor used to determine fair value on an ongoing basis until significant developments or other factors affecting the investment (such as results of the portfolio company's operations, changes in general market conditions, subsequent financings, independent valuations or the availability of market quotations) provide a basis for value other than cost. For investments in which the Company earns an interest for services rendered, the Board estimates the fair value of the services as the initial basis for estimating fair value of the securities received. The Board believes that the methods used to value the investments reflected in the accompanying financial statements have been valued appropriately and that the values reflected herein have been calculated in accordance with generally accepted valuation methods which result in valuations in the Company's financial statements being recorded in accordance with generally accepted accounting principles in the United States. However, losses may occur, which may be material to the financial condition of the Company and proceeds, if any, from the disposition of securities could differ significantly from the values reflected herein. In particular, early stage and seed round investments in private companies, which is the focus of the Company, are typically in illiquid restricted securities with no current market and therefore no market prices or comparables are available upon which to base estimates. These portfolio companies are often development stage with no operations and no positive cash flow. These factors, among others, make determination of fair value more difficult and subject to significant judgment errors by the Company's board of directors.

Stock-based compensation

Adoption of SFAS 123(R)

Until June 30, 2005, we accounted for employee stock options using the intrinsic value method in accordance with Accounting Principles Board Opinion ("APB") No. 25, Accounting for Stock Issued to Employees, and had adopted the disclosure-only alternative of SFAS No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. Under the intrinsic value method, we only recorded stock-based compensation resulting from options granted at below fair market value. Effective July 1, 2005, we adopted SFAS No. 123R, “Share Based Payment”, which requires that we measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award, and recognize that cost over the vesting period.

Valuation and Amortization Method—We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

Expected Term—The expected term represents the period that our stock-based awards are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as influenced by changes to the terms of its stock-based awards.

Expected Volatility—Stock-based payments made prior to July 1, 2005 were accounted for using the intrinsic value method under APB 25. The fair value of stock based payments made subsequent to June 30, 2005 are valued using the Black-Scholes valuation method with a volatility factor based on our historical stock trading history.

Risk-Free Interest Rate—We base the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury securities with an equivalent term.

Estimated Forfeitures—When estimating forfeitures, we considers voluntary termination behavior as well as analysis of actual option forfeitures.

We recognized no stock-based compensation cost in the quarter ended September 30, 2005 because: (a) we have no stock-based awards as of July 1, 2005 that were granted prior to July 1, 2005, and (b) no stock-based awards were granted for the three month period ending September 30, 2005. Restricted stock is expensed based on the fair market value on the grant date.

Because we have no outstanding grants for stock options the Company’s income before income taxes for the three months ended September 30, 2005 was not affected as a result of adopting SFAS 123(R) on July 1, 2005, and there was no impact on cash flow from financing activities.

Loss per share

Table of Contents

Notes to the Unaudited Condensed Financial Statements

~~ENDOVASC,~~(In ~~INC.~~thousands except share data)

~~NOTES~~Gain TO or Loss ~~UNAUDITED~~on ~~CONDENSED FINANCIAL STATEMENTS~~Investments

~~__________~~If the Company's estimates of the future differ from actual events in the future, for any reason, the Company may fail to record an unrecognized gain or loss or may record it later or earlier than it would with a perfect forecast of the future. Because these investments are restricted and illiquid, even if the Company correctly estimates a fair value for an investment today, that investment could lose some or all of its value in the near future without the Company realizing any benefit from its investments or recognizing any cash proceeds from the sale of these investments. If, in the future, the Company determines that a loss has occurred in any of its investments, that loss will be reflected as a reduction in the value of its investments on the Company's statement of net assets, and the reduced values will negatively impact earnings and be reflected as a loss on the statements of operations.

(IN THOUSANDS, EXCEPT SHARE DATA)

If the Company had reported net income for the periods ended June 30, 2005 or September 30, 2005 or for the year ended June 30, 2005, the calculation of diluted net income per share would not have included any additional common equivalent shares.

Concentration of credit risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of investments and cash. The Company places its cash with high credit quality financial institutions. At times in the future, such amounts may exceed the FDIC insured limits.

Revenue Recognition

AsThe ~~a business development company, the~~ Company's revenue ~~will~~is be recognized primarily based on security transactions and related income. Security transactions are accounted for on a trade date basis. Net realized gains or losses on sales of securities are determined on the specific identification method. Interest income and expenses are recognized on the accrual basis. Dividend income is recorded on cumulative preferred equity securities on an accrual basis to the extent that such amounts are expected to be collected and on common equity securities on the record date for private companies or on the ex-dividend date for publicly traded companies. The Company assesses the collectibility of dividends and interest income receivables in connection with its determination of the fair value of the related security. To the extent that there are adverse future developments, previously recognized dividend and interest income may not be realized.

Through ~~September~~December 3031, ~~2005~~2006, the Company had not received any taxable interest or ~~dividend~~taxable dividend income, or any other form of cash income or revenues, nor had it sold ~~any~~ any investments, thus the Company has not recognized any realized gains or ~~losses~~ losses on its investments. When fees are paid to the Company by portfolio companies in their stock, in accordance with generally accepted accounting principles, the Company generally recognizes fee income to the extent of par value in the case of a new company or fair value in the case of an existing company, as determined by the Company's board of directors. Fees paid in shares of the stock of portfolio companies are both restricted and illiquid thus the Company may be unable to convert these shares of stock to cash in the future. Increases or decreases in the fair value of investments above or below accounting cost basis are not included in investment income but are included in the ~~Statement~~statement of ~~Operations~~ operations as unrealized gains or losses until such time as ~~the investment~~ isthe investment is liquidated or sold.

3.New Accounting ~~Going Concern Considerations~~Pronouncements

~~The~~In ~~Company's~~September ~~financial~~2006, ~~statements~~the ~~have~~Financial ~~been~~Accounting ~~prepared~~Standards onBoard a(“FASB”) ~~going~~issued ~~concern~~FASB Statement ~~basis~~No. 157, Fair Value Measurements. FASB Statement No. 157 provides ~~which~~enhanced ~~contemplates~~guidance ~~the~~for ~~realization~~using offair ~~assets~~value ~~and~~to ~~the~~measure ~~settlement~~assets ofand liabilities. FASB ~~and~~Statement ~~commitments~~No. in157 also provides guidance regarding the ~~normal~~extent ~~course~~to ofwhich companies’ ~~business.~~measure ~~The~~assets ~~Company~~and ~~has~~liabilities ~~had~~at ~~recurring~~fair value, the information used to ~~losses~~measure ~~and~~fair ~~continues~~value, toand ~~suffer~~the ~~cash~~effect ~~flow~~of ~~and~~fair ~~working~~value ~~capital~~measurements ~~shortages.~~on ~~Since~~earnings. ~~conversion~~FASB Statement toNo. ~~business~~157 ~~development~~applies ~~corporation~~whenever inother ~~October~~standards ~~2004~~require ~~through~~(or permit) assets ~~September,~~or liabilities ~~30,~~to ~~2005,~~be ~~the~~measured ~~losses~~at ~~totaled~~fair ~~approximately~~value ~~$1,036.~~but Asdoes not expand the use of ~~September~~fair ~~30,~~value ~~2005,~~in ~~the~~any ~~Company~~new ~~had~~circumstances. aFASB ~~working~~Statement ~~capital~~No. ~~deficit~~157 ofis ~~approximately~~effective ~~$310.~~for fiscal ~~These~~years beginning after November 15, 2007, and interim periods within those ~~factors~~fiscal ~~taken~~years, ~~together~~ with ~~the~~early ~~lack~~adoption ofpermitted. ~~revenues~~FASB ~~and~~Statement ~~the~~No. ~~absence~~157 ofis ~~significant~~not ~~financial~~expected ~~commitments~~to ~~raise~~have ~~substantial~~a ~~doubt~~material ~~about~~impact ~~the~~on ~~Company's~~our ~~ability~~financial ~~to continue~~position asor aresults ~~going~~of operations ~~concern~~upon adoption.

In June 2006, the FASB issued FASB Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes (FIN 48). FIN 48 defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authority. This Interpretation defines the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FIN 48 is effective for fiscal years beginning after December 15, 2006. The differences between the amounts recognized in the statements of financial position prior to the adoption of FIN 48 and the amounts reported after adoption will be accounted for as a cumulative-effect adjustment recorded to the beginning balance of retained earnings. We are currently evaluating the effect that the adoption of FIN 48 will have on our financial position and results of operations.

Table of Contents

Notes to the Unaudited Condensed Financial Statements

~~ENDOVASC,~~(In ~~INC.~~thousands except share data)

~~NOTES~~Restatement TO of ~~UNAUDITED~~Prior ~~CONDENSED FINANCIAL STATEMENTS~~Periods

~~__________~~The Statement of Net Assets has been restated for the net assets value per share as of June 30, 2006, to $0.0069 from $0.0017. The restatement is required because it was determined that neither the common stock nor Series NDC common stock is a senior security.

~~(IN~~The ~~THOUSANDS~~ Statement of Cash Flows has been restated for the six months ended December 31, 2005, ~~EXCEPT~~in ~~SHARE~~order to show the effect of granting stock options which had been ~~DATA~~ included in net income (loss).

InThe ~~October~~Financial ~~2004,~~Highlights ~~the~~has ~~Company~~been ~~began~~restated ~~operating~~for asnet aasset ~~business development company~~value, ~~so that~~ itbeginning ~~is no longer a development stage company. Nevertheless, the Company is subject to many~~ of the ~~risks associated with development and early stage~~ ~~companies~~period ~~that~~for ~~lack working capital, operating resources and contracts, cash and ready access to~~ the ~~credit~~change ~~and equity markets. The Company hopes to obtain additional debt and equity financing from various sources~~ in ~~order~~net toshare finance its operations and to continue to grow through investment opportunities. In the event the Company is unable to obtain additional debt or equity financing, the Company will not be able to continue its current level of operations. If the Company is unable to continue its operations, the Company's assets will experience a significant decline in value ~~and the Company will need to rely on funding, if available, in order to continue its limited operations. The Company's continuation~~ as adiscussed going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to comply with the terms of its financing agreements, to obtain additional financing or refinancing as may be required, and ultimately to attain positive cash flows from operations and profits. The Company's investments in ~~portfolio investment companies are reflected on~~ the ~~accompanying~~Statement ~~balance sheets at the board~~ of ~~directors' best estimate of fair value. Because the investments are~~Net ~~illiquid,~~Assets ~~the Company is limited in its ability to sell the investments in its portfolio companies~~above. ~~The value of these investments may decline substantially resulting in the Company receiving little or no cash value for their services and investments in these portfolio companies.~~

3.	Going Concern Considerations

Since its inception as a development stage enterprise, and subsequent to its conversion to a BDC, the Company has not generated significant revenue and has been dependent on debt and equity raised from individual investors to sustain its operations. The Company has conserved cash by issuing its common stock and preferred stock to satisfy obligations, to compensate individuals and vendors and to settle disputes that have arisen. However, during the six months ended December 31, 2006, and December 31, 2005, the Company incurred a net decrease in net assets from operations (in thousands) of $(236) and $(391), respectively, and negative cash flows from operations of $(255) and $(537), respectively. These factors, along with a $(346) negative working capital position at December 31, 2006, raise substantial doubt about the Company’s ability to continue as a going concern.

Management plans to take specific steps to address its difficult financial situation as follows:

o In the near term the Company plans additional private sales of ~~debt and~~ common ~~and preferred~~ stock to ~~qualified~~sophisticated investors to fund its current operations.

o In the long-term, the Company believes that cash flows from ~~commercialization~~dividend distributions by portfolio companies and sales of ~~its products~~investments in portfolio companies will provide the resources for continued operations.

There can be no assurance that the Company’s planned private sales of ~~debt and~~ equity securities ~~securities or its planned public registration of common stock~~ will be successful or that the Company will ~~have~~receive ~~the~~sufficient ~~ability~~cash toflow ~~commercialize~~ from its ~~products~~portfolio ~~and ultimately~~companies ~~attain~~to ~~profitability~~become profitable. The Company’s long-term viability as a going concern is dependent upon ~~three~~four key factors, as follows:

·o The Company’s ability to obtain adequate sources of ~~debt or~~ equity funding to meet current commitments and fund the ~~commercialization~~continued ofinvestment in its ~~products~~portfolio companies.

·o The ~~ability~~receipt of ~~the Company to obtain~~ positive test results offrom ~~its~~clinical ~~products~~trials inby ~~clinical~~the ~~trials~~Company’s portfolio companies.

·o The ~~ability~~effective commercialization of products by the Company’s toportfolio ~~ultimately~~companies ~~achieve~~and ~~adequate~~receipt ~~profitability~~by ~~and~~such portfolio companies of positive cash ~~flows~~flow tofrom ~~sustain~~licensing ~~its~~or ~~operations~~sale of their products.

4.o ~~Notes~~The ~~Payable~~ability ~~Shareholders~~of the Company to sell or otherwise dispose of some or all of its investments in portfolio companies at a price in excess of the aggregate investments made in such portfolio companies.

During the three months ended September 30, 2005 the company repaid $10 to the Company’s Chief Operations Officer (“COO”), which reduced the note payable to the COO to $105 at September 30, 2005.

5. Income Taxes

The difference between the 34% federal statutory income tax rate and amounts shown in the accompanying interim financial statements is primarily attributable to an increase in the valuation allowance applied against the tax benefit from utilization of net operating loss carryforwards.

6. Legal Proceedings

On August 28, 2003, Cause No. 03-08-0681-CV, "The Dow Chemical Company. Endovasc LTD., Inc.," was filed against the Company in the District Court of Montgomery County, Texas, 359th Judicial District. Dow Chemical Company ("Dow") filed a complaint against the Company for breach of contract and damages. The amount of damages sought is approximately $230,000. This case is being vigorously defended against the allegations made by Dow. The Company has filed a counter-claim against Dow for breach of contract and damages. A prediction cannot be made as to the final outcome of the complaint and damages allegedly owed to Dow or the Company. However, management believes it will prevail and accordingly, no amounts have been accrued for this contingency.

Table of Contents

Notes to the Unaudited Condensed Financial Statements

~~ENDOVASC,~~(In ~~INC.~~thousands except share data)

~~NOTES~~Company’s TO cash ~~UNAUDITED~~requirement ~~CONDENSED~~for ~~FINANCIAL~~2007 ~~STATEMENTS~~is expected to be approximately $1,500 or $375 per quarter. The Company does not presently believe that it will receive sufficient funds from sale of portfolio assets or distributions by portfolio companies to fully fund this requirement during 2007.

~~__________~~The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~(IN THOUSANDS,~~4. ~~EXCEPT~~Notes ~~SHARE DATA)~~Payable -Stockholders

OnDuring ~~November 7, 2003, Cause No. 03-11-08112-CV, "Greg Creekmore vs. Endovasc, Inc. and Endovasc, LTD., Inc.," was filed against~~ the ~~Company~~three inmonths ~~the~~ended ~~District~~December ~~Court of Montgomery County~~31, ~~Texas,~~2006 ~~284th Judicial District. Greg Creekmore ("Creekmore") filed a complaint against~~ the Company ~~for~~repaid ~~breach~~$19 ofto ~~a consulting contract between~~ the ~~parties. Creekmore seeks payment of $114,000 plus interest,~~estate ~~one million shares~~ of ~~common stock and reimbursement of court costs including~~ ~~reasonable attorneys' fees allowed by law. This case is being vigorously defended against~~ the ~~allegations~~Company’s ~~made~~former byChief ~~Creekmore.~~Operations AOfficer, ~~prediction~~which ~~cannot~~reduced ~~be made as to~~ the ~~final~~note ~~outcome~~payable ~~of the complaint and damages allegedly owed~~ to ~~Creekmore.~~$80 ~~However,~~at ~~management~~December ~~believes it will prevail and accordingly~~31, ~~no amounts have been accrued for this contingency~~2006.

~~On January 13, 2004, Case No~~5. ~~H-03-5226,~~Income "Lorenz M. Hofmann, Ph.D. and LMH Associates, Inc. vs. Endovasc, LTD., Inc., Endovasc, Inc., David P. Summers, Ph.D. and M. Dwight Cantrell" was filed against the Company in the United States District Court for the Southern District of Texas Houston Division. Lorenz M. Hofmann, Ph.D. and LMH Associates, Inc. ("LMH") filed a complaint against the Company for breach of contract and damages. LMH seeks payment of $91,859. This case is being vigorously defended against the allegations made by LMH. The Company has also filed a counter-claim against LMH for breach of contract and damages. A prediction cannot be made as to the final outcome of the complaint and damages allegedly owed to LMH. However, management believes it will prevail and accordingly, no amounts have been accrued for this contingency.Taxes

The ~~Company~~difference isbetween athe ~~defendant~~34% infederal anstatutory ~~arbitration~~income ~~proceeding~~tax ~~entitled~~rate ~~vFinance Investments~~ and ~~vFinance~~amounts ~~Capital and Endovasc, Ltd., Inc., AAA No. 32 M 181~~shown ~~0011602.~~in ~~vFinance claims an entitlement to certain fees and an unspecified amount of damages for~~ the ~~value~~accompanying ofinterim ~~the~~financial ~~warrants~~statements tois ~~which~~primarily ~~they claim entitlement.~~attributable There was a mediation hearing on December 14, 2004 and no definitive agreement was reached. The cause will move forward into binding arbitration during the latter part of 2005. The Company intends to ~~defend its position vigorously~~an ~~and believes~~increase ~~they will prevail and, accordingly, have not accrued any liability associated with this case~~ in the ~~accompanying~~valuation ~~financial~~allowance ~~statements.~~applied Inagainst ~~October of 2005,~~ the ~~Company~~tax ~~reached~~benefit ~~an agreement with vFinance whereby the Company~~from ~~will pay~~utilization ~~$62,500 as a settlement over a nine month period~~ of ~~time.~~net ~~The~~operating ~~related liability~~loss ~~is recorded in the balance sheet as of September 30, 2005~~carryforwards.

~~In November 2004, the Company filed a lawsuit against its former President & CEO, David P~~6. ~~Summers~~Capital inShare the 284th District Court of Montgomery County, Texas. The suit filed on behalf of the Company alleges a civil conspiracy, breach of fiduciary duty and breach of contract and recision by David P. Summers and seeks restitution and damages in excess of $3.5 million.Transactions

~~The~~For ~~Company~~the three ismonths ~~subject~~ended toDecember ~~certain~~31, ~~other~~2006 ~~legal~~the ~~proceedings~~Company ~~and~~issued ~~claims~~3,000,000 ~~which~~shares ~~arose~~of ~~in the~~common ~~ordinary~~stock ~~course~~with ofa ~~its~~par ~~business.~~value Inof ~~the~~$.001 ~~opinion~~to ofone ~~management,~~individual ~~the~~for ~~amount~~an aggregate ~~of ultimate~~purchase ~~liability~~price ~~with~~of ~~respect~~$70. toThis ~~these~~issuance ~~actions~~increased ~~will~~the ~~not~~number ~~materially~~of ~~affect~~common shares ~~the financial~~issued ~~position,~~and ~~results~~outstanding offrom ~~operations~~157,181,519 orto ~~cash~~160,181,519 ~~flows~~as of ~~the~~December 31, ~~Company~~2006.

7.	Legal Proceedings

On August 28, 2003, Cause No. 03-08-0681-CV, "The Dow Chemical Company vs. Endovasc LTD., Inc.," was filed against the Company in the District Court of Montgomery County, Texas, 359th Judicial District. Dow Chemical Company ("Dow") filed a complaint against the Company for breach of contract and damages. The amount of damages sought is approximately $230. This case is being vigorously defended against the allegations made by Dow. The Company has filed a counter-claim against Dow for breach of contract and damages. This case has been tried and a judgment entered by the district court against the Company. This Company appealed the decision and a prediction cannot be made as to the final outcome of the complaint and damages allegedly owed to Dow or the company. No amounts have been accrued for this contingency.

On November 7, 2003, Cause No. 03-11-08112-CV, "Greg Creekmore vs. Endovasc, Inc. and Endovasc, LTD., Inc.," was filed against the Company in the District Court of Montgomery County, Texas, 284th Judicial District. Greg Creekmore ("Creekmore") filed a complaint against the Company for breach of a consulting contract between the parties. Creekmore seeks payment of $114 plus interest, one million shares of the Company common stock, and reimbursement of court costs including reasonable attorneys' fees allowed by law. This case is being vigorously defended against the allegations made by Creekmore. A prediction cannot be made as to the final outcome of the complaint and damages allegedly owed to Creekmore. However, management believes it will prevail and accordingly, no amounts have been accrued for this contingency.

Table of Contents

Notes to the Unaudited Condensed Financial Statements

~~ENDOVASC,~~(In ~~INC.~~thousands except share data)

~~NOTES~~On TO January ~~UNAUDITED~~13, ~~CONDENSED~~2004, ~~FINANCIAL~~Case ~~STATEMENTS~~No. H-03-5226, "Lorenz M. Hofmann, Ph.D. and LMH Associates, Inc. vs. Endovasc, LTD., Inc., Endovasc, Inc., David P. Summers, Ph.D. and M. Dwight Cantrell" was filed against the Company in the United States District Court for the Southern District of Texas Houston Division. Lorenz M. Hofmann, Ph.D. and LMH Associates, Inc. ("LMH") filed a complaint against the Company for breach of contract and damages. The Company filed a counter-claim against LMH for breach of contract and damages. During the year ended June 30, 2006, the court rendered a decision against the Company in the case. The plaintiff's award, including attorney’ fees, totaled $128. The balance due to LMH at December 31, 2006 is $33.

~~__________~~In November 2004, the Company filed a lawsuit against the former President and CEO, David P. Summers in the 284th District Court of Montgomery County, Texas. The suit filed on Company’s behalf alleges a civil conspiracy, breach of fiduciary duty and breach of contract and rescission by David P. Summers and seeks restitution and damages in excess of $3,500.

~~(IN~~The ~~THOUSANDS~~ Company is subject to certain other legal proceedings and claims which arose in the ordinary course of our business. In the opinion of management, ~~EXCEPT~~the ~~SHARE~~amount ~~DATA)~~ of ultimate liability with respect to these actions will not materially affect our financial position, results of operations or cash flows.

~~ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS~~14

~~The~~Table information contained in this section should be read in conjunction with the Selected Consolidated Financial and Other Data, the Selected Operating Data and our Consolidated Financial Statements and notes thereto appearing elsewhere in this Quarterly Report. This Quarterly Report, including the Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and our assumptions. Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", and "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements including without limitation (1) any future economic downturn could impair our customers' ability to repay our loans and increase our non-performing assets, (2)economic downturns can disproportionately impact certain sectors in which we concentrate, and any future economic downturn could disproportionately impact the industries in which we concentrate causing us to suffer losses in our portfolio and experience diminished demand for capital in these industry sectors, (3) a contraction of available credit and/or an inability to access the equity markets could impair our lending and investment activities, (4) interest rate volatility could adversely affect our results, (5) the risks associated with the possible disruption in our operations due to terrorism and (6) the risks, uncertainties and other factors we identify from time to time in our filings with the Securities and Exchange Commission, including our Form 10-KSBs, Form 10-QSBs and Form 8-Ks. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be incorrect. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report should not be regarded as a representation by us that our plans and objectives will be achieved. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report. Contents

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information contained in this section should be read in conjunction with the Selected Financial and Other Data, the Selected Operating Data and our Financial Statements and notes thereto appearing elsewhere in this Quarterly Report. This Quarterly Report, including the Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and our assumptions. Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", and "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be incorrect. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report should not be regarded as a representation by us that our plans and objectives will be achieved. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report.

CRITICAL ACCOUNTING POLICIES

We believe that of the significant accounting policies used in the preparation of our financial statements (See Note 1 to the audited financial statements for the year ended June 30, ~~2005~~2006), the following are critical accounting policies, which may involve a higher degree of judgment, complexity and estimates.

SIGNIFICANT ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term.

INVESTMENTS

Investments are reported at fair ~~market~~ value. The most significant estimate inherent in the preparation of our ~~consolidated~~ financial statements is the valuation of ~~its~~our investment ~~investment~~ and the related unrealized appreciation or depreciation. ~~Upon~~We ~~our conversion~~employ ~~to a business development company, we employed~~ an independent business valuation expert to value our portfolio companies. The Board of Directors determined all portfolio companies and investments at fair ~~market~~value ~~value~~ under a good faith standard.

STOCK-BASED COMPENSATION

Adoption of SFAS 123(R)

Until June 30, 2005, we accounted for employee stock options using the intrinsic value method in accordance with Accounting Principles Board Opinion ("APB") No. ~~25,~~ 25, Accounting for Stock Issued to Employees, and had adopted the disclosure-only alternative of SFAS No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure which requires pro-forma disclosure ~~Disclosure.~~of compensation expense associated with stock options under the fair value method. Under the intrinsic value method, we only recorded stock-based compensation ~~compensation~~ resulting from options granted at below fair market value. Effective ~~Effective~~ July 1, 2005, we adopted SFAS No. 123R, “Share Based Payment”, which requires that wethey measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the ~~award,~~ award, and recognize that cost over the vesting period.

Table of Contents

Valuation and Amortization Method—We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

Expected Term—The expected term represents the period that our stock-based awards are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as influenced by changes to the terms of its stock-based awards.

Expected Volatility—Stock-based payments made prior to July 1, 2005 were accounted for using the intrinsic value method under APB 25. The fair value of stock based payments made ~~subsequent~~ subsequent to ~~June~~ June 30, 2005 ~~are~~is valued using the Black-Scholes valuation method with a volatility factor based on our historical stock trading history.

Table of Contents

ENDOVASC, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

__________

(IN THOUSANDS, EXCEPT SHARE DATA)

Risk-Free Interest Rate—We base the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury securities with an equivalent term.

Estimated Forfeitures—When estimating forfeitures, we ~~considers~~consider voluntary termination behavior as well as analysis of actual option forfeitures.

WeOn ~~recognized~~October no21, ~~stock-based~~2005, ~~compensation~~our ~~cost~~Board inof Directors adopted the ~~quarter~~2005 ~~ended~~Executive ~~September~~Compensation ~~30, 2005~~Plan ~~because:~~ (athe “Plan”). weAmendment ~~have~~No. no1 ~~stock-based~~to ~~awards~~the asPlan ofwas ~~July~~adopted 1,by ~~2005~~the ~~that~~Board ~~were~~of ~~granted~~Directors ~~prior~~on toNovember ~~July~~14, 12005. On December 16, 2005, the stockholders approved the 2005 Plan and ~~(b)~~the nogrant of certain stock~~-based~~ ~~awards~~options ~~were~~under ~~granted~~the ~~for~~Plan. The maximum ~~the~~number ~~three~~of ~~month~~shares ~~period~~currently ~~ending~~reserved ~~September~~for ~~30,~~issuance ~~2005.~~is ~~Restricted~~equal ~~stock~~to is15% ~~expensed~~of the number ~~based~~of onshares ~~the~~of ~~fair~~Common ~~market~~Stock ~~value~~issued onand ~~the~~outstanding ~~grant~~at ~~date.~~any time.

~~Because~~We weare not ~~have~~presently noable ~~outstanding~~to ~~grants~~compensate ~~for~~our ~~stock~~officers ~~options~~and ~~the~~employees ~~Company’s~~with ~~income~~cash ~~before~~because ~~income~~of the ~~taxes~~lack ~~for~~of ~~the~~available ~~three~~funds ~~months~~from ~~ended~~operations. ~~September~~The ~~30,~~Plan ~~2005~~ was ~~not~~adopted ~~affected~~to provide as a ~~result~~means ofby ~~adopting~~which ~~SFAS~~we ~~123(R)~~can onattract ~~July~~and 1,retain ~~2005,~~officers and ~~there~~employees ~~was~~and nogive ~~impact~~such officers onand employees an interest in our success. Under the Plan, the Board ~~cash~~of ~~flow~~Directors ~~from~~(or ~~financing~~a ~~activities~~committee designated by the Board of Directors) may grant options to purchase shares of our Common Stock to officers and employees. Directors are not eligible to receive options under the Plan.

LOSS PER SHARE

Basic and diluted loss per share is computed on the basis of the weighted average number of shares of common stock outstanding during each period. Common equivalent shares from common stock options and warrants and convertible preferred stock are excluded from the computation for the three months ended September 30, 2005 and 2004 as their effect would dilute the loss per share for these periods. If we had reported net income during the three months ended September 30, 2005 and 2004 the calculation of diluted net income per share would have included 208 additional common equivalent shares.

CONCENTRATION OF CREDIT RISK

Financial instruments which potentially subject ~~the~~us ~~Company~~ to concentrations of credit risk ~~risk~~ consist principally of investments and cash. ~~The~~We ~~Company~~place ~~places~~our ~~its~~ cash with high credit quality financial institutions. At times in the future, such amounts may exceed the FDIC insured limits.

OVERVIEW

Endovasc, Inc. is a Nevada corporation and the successor to a biopharmaceutical company incorporated on June 10, 1996. Effective September 17, 2004, most of our assets and liabilities were transferred to wholly owned subsidiaries, and we became an internally managed "Non-diversified Closed-end Company" as defined by Section 5 of the Investment Company act of 1940 (the "40 Act") that elected to be treated as a "Business Development Company" pursuant to Section 54 of the 40 Act. We will not elect to be treated for federal income tax purposes as a regulated investment company under the Internal Revenue Code with the filing of its federal corporate income tax return for 2005.

PORTFOLIO INVESTMENTS

Investments are reported at fair value. The most significant estimate inherent in the preparation of our financial statements is the valuation of our investments and the related unrealized appreciation or depreciation. We employ an independent business valuation expert to value our portfolio companies. The Board of Directors determined all portfolio companies and investments at fair value under a good faith standard.

Upon our conversion to a business development company, we employed an independent business valuation expert to value our portfolio companies. The Board of Directors determined all portfolio companies and investments at fair value under a good faith standard.

We currently have investments in five portfolio companies as follows:

1. Liprostin, Inc.

We have aninvested ~~investment~~ in Liprostin, Inc., a wholly-owned portfolio company ~~Liprostin,~~engaged ~~Inc. (“Liprostin”),~~in ~~which~~obtaining isFDA ~~engaged~~approval ~~in the development~~ of ~~liposome~~a ~~drug~~liposomal ~~delivery~~encapsulated ~~systems.~~form Weof ~~are~~Prostaglandin 1-E ~~having~~(“PGE-1”) ~~exceptional~~for ~~reception~~the ~~of this~~ treatment inof ~~the~~intermittent ~~European community~~claudication.

Table of Contents

ENDOVASC, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

__________

(IN THOUSANDS, EXCEPT SHARE DATA)

We continue to work on revisions to the protocol for submissions to the FDA. Due to the slow progress of the protocol revisions, we have decreased our valuation of this portfolio from $400,000 to $250,000.

2. Nutraceutical Development Corporation

We have an investment in a wholly-owned portfolio company, Nutraceutical Development Corporation (“NDC”), which develops certain technologies for use in dietary products designed to enhance health and provide beneficial biological effects (“nutraceuticals”).

During this quarter, the product was launched and sales were reported at 1,100,000 resulting in net royalties of $98,000. We anticipate a significant increase in sales during the quarter ending December 2005. Based on cash flow method, we have increased our evaluation of this portfolio from $175,000 to $450,000.

3. Endovasc-TissueGen Research Sponsors, L.L.C.

We have a 49.9% investment in a joint venture named Endovasc-TissueGen Research Sponsors, L.L.C. (the “Partnership”). The purpose of the Partnership is to develop a bioresorbable drug-eluting cardiovascular stent for the advanced treatment of coronary artery disease.

4. Endovasc-TissueGen-Blumberg Research Sponsors, L.L.C.

We have a 39.9% investment in a joint venture named Endovasc-TissueGen Blumberg Research Sponsors, L.L.C. (the “Joint Venture”). The purpose of the Joint Venture is to develop biodegradable stents for ureteral and prostate applications.

5. Angiogenix Ltd., Inc

Angiogenix had an exclusive licensing agreement (the "Stanford License Agreement") with the Board of Trustees of the Leland Stanford University relating to US Patent Application 60/146,233 (issued as US Patent No. 6,417,205 B1 on July 9, 2002) relating to the administration of Nicotine or Nicotine Receptor Agonist (NRA) to induce the growth of new blood vessels ("angiogenesis"). During the quarter ended June 30, 2005, we cancelled our license agreement with Leland J. Stanford University. The evaluation of the research done on this project has been written down to $5,000 for the quarter ended September 30, 2005.

RESULTS OF OPERATIONS THREE MONTH SEPTEMBER 30, 2005 AND 2004 (IN THOUSANDS)

During the quarter ended September, 30, 2005 our income increased to $38 compared with income of $ -0- for the quarter ended September, 30, 2004. This increase is a result of management fees from our portfolio companies.

During the quarter ended September 30, 2005, operating, general and administrative expenses were $229 compared to $594 for the quarter ending September 30, 2004. The decrease is primarily due to a decrease in public relations and consulting fees.

Research and development expenses totaled $-0- during the three months ending September 30, 2005, a decrease of $86 from $86 for the three months ended September, 2004. This decrease results from portfolio companies reflecting research and development expenses.

Cash flows used in operating activities for the three months ended September 30, 2005 decreased $41 to $174 compared to $133 for the three months ended September 30, 2004, primarily due to a decrease in cash spent on research and development.

LIQUIDITY AND CAPITAL RESOURCES (IN THOUSANDS)

We had a working capital deficit at September 30, 2005 of $310, compared to a deficit of $285 at June 30, 2005. This decrease in primarily due to a decrease in liabilities partially offset by a decrease in current assets.

Table of Contents

~~ENDOVASC~~Liprostin, ~~INC~~Inc. conducted a successful Phase I clinical trial to test product safety and tolerance levels using a small group of healthy subjects in January 2001. Based on the results of this trial, and the previously established safety profile of PGE-1, the FDA recommended that we proceed to a Phase III trial to determine the safety and efficacy of the administration of Liprostin™ PGE-1 in combination with angioplasty for the treatment of intermittent claudication or critical limb ischemia. In 2003, Liprostin, Inc. submitted a protocol for the phase II clinical study entitled “A Phase II, Open label, Multi-center study of Liposomal prostaglandin E-1 (Liprostin™) in Patients with Critical Limb Ischemia and Intermittent Claudication”. The Phase II clinical trial consisting of 73 patients was initiated in December 2003 and concluded in August 2004. The successful results of this trial for peripheral arterial occlusive disease were presented to the FDA in the fall of 2004. Liprostin, Inc. will conduct a Phase IIIa trial to establish efficacy and safety profile in order to seek or enter into a partnership with a suitable company to co-develop and market Liprostin™ PGE-1 for treatment of peripheral vascular disease. Opportunities to out-license or sell the technology are also being considered by Liprostin, Inc.

~~NOTES~~Angiogenix TOLimited, ~~UNAUDITED CONDENSED FINANCIAL STATEMENTS~~Inc.

~~__________~~We have invested in Angiogenix Limited, Inc., a wholly-owned portfolio company that previously held an exclusive licensing agreement (the "Stanford License Agreement") relating to US Patent No. 6,417,205 B1 relating to the administration of Nicotine or Nicotine Receptor Agonist (NRA) to induce the growth of new blood vessels ("angiogenesis"). During the year ended June 30, 2005, we cancelled our Stanford License Agreement and Angiogenix Limited, Inc. ceased operations.

~~(IN~~Nutraceutical ~~THOUSANDS,~~Development ~~EXCEPT SHARE DATA)~~Corporation

~~Our~~The ~~continuation~~Company ashas ainvested ~~going~~in ~~concern~~Nutraceutical isDevelopment ~~dependent~~Corporation, ~~upon our ability to generate sufficient cash flow to meet our obligations on~~ a ~~timely basis, to comply with~~wholly-owned ~~the~~portfolio ~~terms~~company ofengaged ~~our financing agreements, to obtain additional financing or refinancing as may be required, and ultimately to attain positive cash flows from operations and profits. Our investments~~ in ~~our portfolio investment companies are reflected on~~ the ~~accompanying~~development ~~balance sheets at the board~~ of ~~directors'~~ ~~best~~certain ~~estimate~~technologies offor ~~fair value. Because the investments are illiquid,~~use wein ~~are~~dietary ~~limited~~products indesigned ~~our ability~~ to ~~sell~~enhance ~~the~~health ~~investments in our portfolio companies. The value of these investments may decline substantially resulting in us receiving little or no cash value for our services~~ and ~~investments~~provide inbeneficial ~~these~~biological ~~portfolio companies~~effects.

~~These~~In ~~events~~2002, Nutraceutical ~~raise~~Development ~~doubt~~Corporation asbegan toexperimentation ~~our~~in ~~ability~~mice to demonstrate ~~continue~~accelerated asmuscle mass was achieved when fed very low doses of certain compounds in drinking water combined with extensive exercise during a three ~~going~~week ~~concern~~regimen. The ~~report~~mice that were given low amounts developed a significant ofmuscle ~~our~~increase ~~independent~~compared ~~public~~to ~~accountants,~~the ~~which~~controlled ~~accompanied~~mice. ~~our~~A ~~financial~~scientifically controlled ~~statements~~double ~~for~~blind, double placebo study in healthy weight lifters confirmed the earlier ~~year~~animal ~~ended~~results ~~June~~and 30in August of 2003 Nutraceutical Development Corporation filed Patent Application Serial No.10/633,325 ~~2005~~relating to this discovery. United States Patent No. 7,074,812 ~~was~~B2; ~~qualified~~Development of ~~with~~Muscle ~~respect~~Mass toin a Mammal ~~that~~was ~~risk~~issued on July 11, 2006. InThe ~~order~~technology was licensed to ~~continue~~Basic asResearch, L.L.C. in July 2003 for the development of a ~~going~~dietary ~~concern~~supplement, weEndothil ~~must~~- ~~raise~~CR™, ~~additional funds~~which asis presently distributed through GNC stores nationwide. Nutraceutical ~~noted~~Development ~~above~~Corporation ~~and~~receives ~~ultimately~~a ~~achieve~~royalty ~~profit~~on ~~from~~sales ~~our~~of ~~operations~~Endothil - CR™ supplements.

~~ITEM~~Endovasc-TissueGen Research 3Sponsors, ~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~L.C.C.

~~Interest~~The ~~rate~~Company ~~sensitivity~~has ~~refers~~invested ~~to the change~~ in ~~earnings~~Endovasc-TissueGen ~~that~~Research ~~may~~Sponsors, ~~result~~L.L.C., ~~from~~a ~~the~~49.9% ~~changes~~owned inlimited ~~the~~liability ~~level~~company ofengaged ~~interest~~in ~~rates.~~the ~~Our~~development ~~net~~of ~~interest~~a ~~income can be affected~~bioresorbable bydrug-eluting ~~changes~~cardiovascular instent ~~various~~for ~~interest~~the ~~rates,~~advanced ~~including~~treatment ~~LIBOR,~~of ~~prime~~coronary ~~rates and~~artery ~~commercial paper rates~~disease.

AsEndovasc-TissueGen-Blumberg ~~a business~~Research ~~development company~~Sponsors, ~~we use a greater portion of equity to fund our business~~L. Accordingly, other things being equal, increases in interest rates will result in greater increases in our net interest income and reductions in interest rates will result in greater decreases in our net interest income compared with the effects of interest rate changes on our results under more highly leveraged capital structuresC. C

~~Currently,~~The weCompany dohas ~~not~~invested ~~engage~~ in ~~hedging~~Endovasc-TissueGen-Blumberg ~~activities~~Research ~~because~~Sponsors, ~~we have determined that the~~L.L.C., ~~cost~~a of39.9% ~~hedging~~owned ~~the~~limited ~~risks~~liability ~~associated~~company ~~with~~engaged ~~interest~~in ~~rate changes outweighs~~ the ~~risk~~development of ~~reductions~~biodegradable ~~benefit.~~stents Wefor ~~monitor~~ureteral ~~this~~and ~~position~~prostate ~~on an ongoing basis~~applications.

~~ITEM~~MATERIAL CHANGES 4IN ~~CONTROLS~~FINANCIAL ~~AND PROCEDURES~~CONDITION

AsMaterial ~~of September~~changes ~~30,~~in ~~2005,~~financial wecondition ~~carried~~since ~~out~~June ~~an evaluation~~30, ~~under~~2006 ~~the~~consist ~~supervision~~primarily ~~and with the participation~~ of ~~management, including~~ the ~~Chief Executive Officer and~~ ~~Chief Financial~~investments ~~Officer,~~being ofstated ~~the~~at ~~effectiveness~~an ofincrease ~~the design and operation of our disclosure controls and procedures (as defined~~ in ~~Exchange~~fair ~~Act~~value ~~Rule~~from ~~13a-15(e) and Rule 15d-15(e)). Based upon that evaluation~~$1,605,000 ~~our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective at a reasonable level in timely alerting them~~ to ~~material~~ ~~information~~$2,000,000, ~~relating to Endovasc that is required to be included in our filings with~~ the ~~Securities~~receipt ~~and~~of ~~Exchange~~subscriptions ~~Commission.~~receivable ~~There~~of ~~has~~$25,000 ~~been~~shown noon ~~change in our internal control over financial reporting that occurred during~~ the ~~most recent~~ ~~fiscal~~Statement ~~quarter~~of ~~that~~Net ~~has~~Assets ~~materially~~as ~~affected~~of orJune is30, ~~reasonably~~2006, ~~likely to materially affect our internal control over financial reporting.~~

Our management, including the Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met due to numerous factors, ranging from errors to conscious acts of an individual, or individuals acting together. In addition, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, misstatements due to error and/or fraud may occur and not be detected.

Table of Contents

~~ENDOVASC,~~RESULTS ~~INC.~~OF OPERATIONS - THREE MONTHS ENDED DECEMBER 31, 2006 and 2005

~~NOTES~~For TOthe quarter ~~UNAUDITED~~ended ~~CONDENSED~~December ~~FINANCIAL~~31, ~~STATEMENTS~~2006 the revenue decreased when compared to the quarter ended December 31, 2005 by $43,000 due primarily to the cessation of payments from one of our wholly owned subsidiary companies and reimbursable expenses from another. The operating expenses decreased by $110,000 from the quarter ended December 31, 2005 due stock options expense recognition during the quarter ended December 31, 2005.

~~__________~~RESULTS OF OPERATIONS - SIX MONTHS ENDED DECEMBER 31, 2006 and 2005

~~(IN~~For ~~THOUSANDS~~the six months ended December 31, ~~EXCEPT~~2006 ~~SHARE~~revenue was comparable to the six months ~~DATA)~~ended December 31, 2005. Operating expenses for the six months ended December 31, 2006 decreased by $153,000 from the quarter ended December 31, 2005 due primarily to stock options expense recognition during the six months ended December 31, 2005.

Net cash flows for the six months ended December 31, 2006 increased over the net cash flows for the six months ended December 31, 2005 by $117,000 due primarily to stock options expense recognition.

LIQUIDITY AND CAPITAL RESOURCES

On December 31, 2006, our cash and cash equivalents were $30,000. We had a working capital deficit at December 31, 2006 of $346,000 compared to a deficit of $384,000 at June 30, 2006. This decrease is primarily due a reduction in notes and accounts payable and an increase in our cash position.

Our continuation as a going concern is dependent upon the receipt of sufficient cash flow from our portfolio companies to meet our obligations on a timely basis. Our investments in our portfolio companies are reflected on the accompanying statements of net assets at the board of directors' best estimate of fair value. Because the investments are illiquid, we are limited in our ability to sell the investments in our portfolio companies. The value of these investments may decline substantially resulting in us receiving little or no cash value for our services and investments in these portfolio companies.

These events raise doubt as to our ability to continue as a going concern. The report of our independent public accountants, which accompanied our financial statements for the year ended June 30, 2006, was qualified with respect to that risk. In order to continue as a going concern, we must raise additional funds as noted above.

ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our functional currency is the U.S. dollar.

Our investment activities contain elements of risk. The portion of our investment portfolio consisting of equity or equity-linked debt securities in private companies is subject to valuation risk. Because there is typically no public market for the equity and equity-linked debt securities in which we invest, the valuation of the equity interest in the portfolio is stated at “fair value” and determined in good faith under the direction of our Board of Directors on a quarterly basis in accordance with our investment valuation policy.

In the absence of a readily ascertainable market value, the estimated value of our portfolio may differ significantly from the value that would be placed on the portfolio if a ready market for the investments existed. Any changes in valuation are recorded in our Statement of Operations as “Net unrealized appreciation (depreciation) on investments”.

As of December 31, 2006, we have no off-balance sheet investments or hedging investments.

We do not believe that our business is materially affected by inflation, other than the impact inflation may have on the securities markets, the valuations of business enterprises and the relationship of such valuation to underlying earnings, all of which will influence the value of our investments.

Table of Contents

ITEM 4

CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. An evaluation made at the end of the period covered by this report was performed under the supervision and with the participation of our president, chief executive officer ("CEO") and the chief financial officer ("CFO") of the effectiveness of the design and operation of our disclosure controls and procedures to insure that we record, process, summarize and report in a timely and effective manner the information required to be disclosed in reports filed with or submitted to the Securities and Exchange Commission. Due to the limited number of employees engaged in the authorization, recording, processing and reporting of transactions, there is inherently a lack of segregation of duties. We periodically assess the cost versus benefit of adding the resources in connection with the design and operation of disclosure controls and procedures. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective in timely bringing to their attention material information required to be included in our periodic Securities and Exchange Commission filings.

(b) Changes in Internal Controls Over Financial Reporting. There have been no significant changes in internal control over financial reporting that occurred during the fiscal period covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II

ITEM 1

LEGAL PROCEEDINGS

OnExcept ~~August~~as ~~28,~~set ~~2003,~~forth ~~Cause No. 03-08-0681-CV~~above, ~~"The~~there ~~Dow~~have ~~Chemical~~been ~~Company~~no ~~vs.~~material ~~Endovasc~~developments ~~LTD., Inc.," was filed against us~~ in the ~~District Court of Montgomery County, Texas,~~legal ~~359th~~proceedings ~~Judicial~~disclosed ~~District.~~in ~~Dow~~the ~~Chemical~~ Company’s ~~("Dow")~~Annual ~~filed~~Report aon ~~complaint~~Form ~~against the~~10-K ~~Company~~ for ~~breach~~the ~~of contract and damages. The amount of damages sought~~year ~~is approximately~~ended ~~$230~~June 30,~~000.~~ ~~This case is being vigorously defended against the allegations made by Dow~~2006. We ~~have~~are ~~also~~subject ~~filed~~to acertain ~~counter-claim~~other ~~against~~legal ~~Dow~~proceedings ~~for~~and ~~breach~~claims ofwhich ~~contract~~arose ~~and~~in ~~damages.~~the Aordinary ~~prediction~~course ~~cannot~~of beour ~~made~~business. asIn to the ~~final~~opinion of ~~outcome~~management, of the ~~complaint~~amount ~~and~~of ~~damages~~ultimate ~~allegedly~~liability ~~owed~~with torespect ~~Dow or~~ to ~~us.~~these ~~However,~~actions ~~management~~will not ~~believes~~materially itaffect ~~will~~our ~~prevail~~financial ~~and accordingly~~position, noresults ~~amounts~~of ~~have~~operations ~~been~~or cash ~~accrued for this contingency~~flows.

~~On November~~ITEM 7,1A ~~2003,~~Risk Cause No. 03-11-08112-CV, "Greg Creekmore vs. Endovasc, Inc. and Endovasc, LTD., Inc.," was filed against us in the District Court of Montgomery County, Texas, 284th Judicial District. Greg Creekmore ("Creekmore") filed a complaint against us for breach of a consulting contract between the parties. Creekmore seeks payment of $114,000 plus interest, one million shares of our common stock and reimbursement of court costs including reasonable attorneys' fees allowed by law. This case is being vigorously defended against the allegations made by Creekmore. A prediction cannot be made as to the final outcome of the complaint and damages allegedly owed to Creekmore. However, management believes it will prevail and accordingly, no amounts have been accrued for this contingency. Factors

OnPotential ~~January~~ Ineligibility ~~13,~~as ~~2004,~~a ~~Case~~Business NoDevelopment Company. ~~H-03-5226,~~The company ~~"Lorenz~~has M.received ~~Hofmann,~~correspondence ~~Ph.D.~~from the Securities and ~~LMH~~Exchange Commission ~~Associates,~~ questioning ~~Inc.~~whether ~~vs.~~or ~~Endovasc,~~not ~~LTD.,~~the ~~Inc.,~~Company ~~Endovasc,~~is ~~Inc.,~~eligible ~~David~~to P.be ~~Summers,~~treated as a business ~~Ph.D.~~ development ~~and~~company M.because ~~Dwight~~substantially ~~Cantrell"~~all ~~was~~of ~~filed~~its ~~against~~portfolio uscompanies are wholly-owned. inThe ~~the~~Company ~~United~~believes ~~States~~that ~~District~~it is qualified as a business ~~Court~~ development ~~for~~company ~~the~~because ~~Southern~~it ~~District~~is ofengaged ~~Texas~~primarily ~~Houston~~in ~~Division.~~the ~~Lorenz~~business M.of investing, ~~Hofmann~~reinvesting, ~~Ph.D.~~ and ~~LMH~~trading ~~Associates,~~in ~~Inc~~securities. ~~("LMH")~~In ~~filed~~addition, athe ~~complaint~~Company could ~~against~~be usliable for ~~breach of~~substantial afines ~~consulting~~and ~~contract~~penalties ~~and~~in ~~damages.~~connection ~~LMH~~with ~~seeks~~its previous ~~payment~~certification ofthat ~~$91,859.~~it ~~This~~qualifies ~~case~~as a business development company is which ~~being~~ could ~~vigorously~~have ~~defended~~an ~~against~~adverse ~~the~~effect ~~allegations~~on ~~made~~the byCompany’s ~~LMH~~financial condition. WeThe ~~have also~~Company ~~filed~~ disagrees ~~our~~with ~~own~~the ~~counter-claim~~comments ~~against~~of ~~LMH~~the ~~for~~Securities ~~breach~~and ofExchange ~~contract~~Commission and ~~damages.~~ A has ~~prediction~~ made ~~cannot~~a befull ~~made~~response. asIf toit ~~the~~should ~~final~~be ~~outcome~~determined ofby the ~~complaint.~~SEC ~~However,~~that any ~~management~~ deficiencies ~~believes~~exist, itthe ~~will~~Company ~~prevail~~may ~~and~~be ~~accordingly,~~liable nofor ~~amounts~~fines ~~have~~and ~~been~~penalties which ~~accrued~~ may have ~~for~~an ~~this~~adverse ~~contingency~~effect on the Company’s financial condition.

~~The~~Potential ~~Company~~ Liability isUnder athe ~~defendant~~Investment inCompany anAct ~~arbitration~~of ~~proceeding~~1940. ~~entitled vFinance~~The ~~Investments~~ Company ~~and~~has ~~vFinance~~received ~~Capital~~correspondence ~~and~~from ~~Endovasc,~~the ~~Ltd.,~~Securities ~~Inc.,~~and ~~AAA~~Exchange ~~No.~~Commission questioning 32whether Mor ~~181 0011602.~~not ~~vFinance~~the ~~claims~~Company anhas ~~entitlement~~failed to ~~certain~~comply ~~fees~~with ~~and an unspecified~~various ~~amount~~ provisions of ~~damages~~the ~~for~~Investment ~~the~~Company ~~value~~Act of 1940, including the ~~warrants~~existence of tothe Series ~~which~~NDC ~~they~~common ~~claim~~stock, ~~entitlement. There~~failure ~~was~~to have a ~~mediation~~board ~~hearing~~of ondirectors ~~December~~consisting of ~~14,~~a majority ~~2004~~of ~~and~~non-interested nopersons, ~~definitive~~failure ~~agreement was~~to ~~reached.~~have ~~The~~an ~~cause~~effective ~~will~~chief compliance ~~move~~officer, ~~forward~~and ~~into~~failure ~~binding~~to ~~arbitration~~obtain ~~during~~an ~~the latter~~appropriate ~~part~~surety ~~of 2005~~bond. The Company ~~intends~~disagrees towith ~~defend~~these ~~its~~claims ~~position vigorously~~ and ~~believes~~ ~~they~~has ~~will~~made ~~prevail~~a timely and, ~~accordingly,~~prompt ~~have~~response addressing ~~not~~these ~~accrued~~issues. ~~any~~The ~~liability associated~~Company disagrees with ~~this case in~~ the ~~accompanying~~comments ~~financial~~of ~~statements. In October~~the of Securities ~~2005,~~and ~~the~~Exchange ~~Company~~Commission ~~reached~~and anhas ~~agreement~~made ~~with~~a ~~vFinance~~full ~~whereby~~response. ~~the~~If ~~Company~~it should ~~will~~ be ~~pay~~ determined ~~$62,500~~by asthe aSEC ~~settlement~~that ~~over~~any adeficiencies ~~nine~~exist, ~~month~~the ~~period~~Company ofmay ~~time.~~be ~~The related~~liable ~~liability~~ for fines isand ~~recorded~~penalties inwhich ~~the~~may ~~balance~~have ~~sheet~~an asadverse ofeffect ~~September~~on ~~30,~~the Company’s financial ~~2005~~ condition.

InPotential ~~November~~ Liability ~~2004,~~Under wethe ~~filed~~Securities aAct ~~lawsuit~~of ~~against~~1933. The Company ~~our~~has ~~former~~received ~~President~~correspondence from the Securities and ~~CEO,~~Exchange ~~David~~Commission P. questioning whether or not the Company may have violated the Securities Act ~~Summers~~ of 1933 in ~~the~~connection ~~284th~~with ~~District~~certain ~~Court~~offerings of ~~Montgomery~~its ~~County,~~common ~~Texas~~stock pursuant to Regulation E. The ~~suit~~Company ~~filed~~disagrees with the comments of the Securities and on Exchange ~~our~~Commission ~~behalf~~and ~~alleges~~has made a ~~civil~~full ~~conspiracy,~~response. ~~breach~~If ofit ~~fiduciary~~should ~~duty~~be ~~and breach~~determined of by ~~contract~~ the ~~and~~SEC ~~rescission~~that byany ~~David~~deficiencies P.exist, ~~Summers~~the ~~and~~Company ~~seeks~~may ~~restitution~~be ~~and~~liable ~~damages~~for fines in and ~~excess~~ penalties ofwhich ~~$3.5~~may ~~million.~~have an adverse effect on the Company’s financial condition.

We are subject to certain other legal proceedings and claims which arose in the ordinary course of our business. In the opinion of management, the amount of ultimate liability with respect to these actions will not materially affect our financial position, results of operations or cash flows.19

Table of Contents

~~ENDOVASC~~Potential Unavailability of Exemptions From Registration. If the Company is determined to not be eligible to elect business development company status, it may not qualify for the exemption from registration of its securities ~~INC~~ pursuant to Regulation E under the Securities Act of 1933. If it is determined that the company does not qualify, under the Investment Company Act of 1940 or the Securities Act of 1933, it will not qualify for certain exemptions from registration of its securities pursuant to Regulation D under the Securities Act of 1933. In the event an order is entered by the Securities and Exchange Commission, the Company would be unable to raise additional capital under an exemption from registration. The Company disagrees with the comments of the Securities and Exchange Commission and has made a full response. If it should be determined by the SEC that any deficiencies exist, the Company may be liable for fines and penalties which may have an adverse effect on the Company’s financial condition.

~~NOTES TO~~ITEM ~~UNAUDITED~~2 ~~CONDENSED~~Unregistered ~~FINANCIAL~~Sales ~~STATEMENTS~~of Securities and Use of Proceeds

~~__________~~During the six months ended December, 31, 2006 we issued an aggregate of 13,497,500 shares of common stock to two sophisticated investors for an aggregate purchase price of $325,000 pursuant to Regulation E under the Securities Act of 1933.

(IN THOUSANDS, EXCEPT SHARE DATA)

ITEM 2 Unregistered Sales of Securities

In October of 2004 a form 1-E filing was made which indicated our intent to raise capital under regulation E. During the three months ended September 30, 2005, the following transactions were effected by us in reliance upon exemptions from registration under the Securities Act of 1933 as amended (the "Act"). Unless stated otherwise, we believe that each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition. No underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions. These transactions did not involve a public offering. Each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Act and setting forth the restrictions on the transferability and the sale of the securities. During the three months ended September 30, 2005, we issued 7,105,390 shares of common stock to 4 individuals with an aggregate value of $235,900. These transactions were exempt from registration pursuant to Section 4(2) of the Act.

ITEM 3

Defaults Upon Senior Securities

None.

ITEM 4

Submission of Matters to a Vote of Security Holders

~~None.~~The Company held its Annual Meeting of Stockholders on December 21, 2006, at which the stockholders took the following actions:

1.	Election of Directors:

	For	Withheld
Diane Dottavio	147,286,348	3,771,024
Donald Leonard	147,720,433	3,334,945

The following directors’ term of office continued after the meeting:

Thomas Hall

Dale Greenwald

2. Approval of McConnell & Jones LLP as Registered Public Accounting firm of the Company for the year ending June 30, 2007

For		Against		Abstain
137,562,909		2,805,474		387,407

3. To amend the Certificate of Designation of Powers, Preferences, Limitation, and Relative Rights for the Series NDC Stock to permit the redemption thereof by the company

For		Against		Abstain		Non-Vote
3,019,815		2,533,256		10,832		4,729,565

ITEM 5

Other Information

None.

ITEM 6

Exhibits

	31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

1931.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

ENDOVASC, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

__________

(IN THOUSANDS, EXCEPT SHARE DATA)

SIGNATURES

In accordance with the requirements of Sections 13 and 15(d) of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

	ENDOVASC, INC.		~~ENDOVASC, INC.~~
Date:	November 18, 2005			By:	/s/ Diane Dottavio
Date: February 20, 2007		By:	/s/ Diane Dottavio
		Diane Dottavio		~~Diane Dottavio~~
		Chief Executive Officer		~~Chief Executive Officer~~
Date:	November 18, 2005			By:	/s/ Clarice Motter
Date: February 20, 2007		By:	/s/ Sam Lindsey
				Clarice Motter
		Sam Lindsey
		Chief Financial Officer		~~Chief Financial Officer~~

2021

Filing Compare · ENDOVASC INC